Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | AR | P10275 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | GAK | O14976 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.34 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18484464 | 0.84 | SRC (0.47) | SRCARKDM4EUSP2ALDH1A1 | |
| SCHEMBL2733313 | 0.82 | ACHE (0.50) | KDM4EALDH1A1HPGDACHECYP3A4 | |
| SCHEMBL14806539 | 0.80 | AR (0.33) | ARHPGDIMPDH2 | |
| SCHEMBL14805868 | 0.78 | ALDH1A1 (0.54) | ARKDM4EUSP2ALDH1A1IMPDH2 | |
| SCHEMBL31432852 | 0.73 | ACHE (0.61) | SRCARKDM4EUSP2ALDH1A1 | |
| SCHEMBL16122429 | 0.73 | AR (0.33) | AR | |
| SCHEMBL31095269 | 0.72 | KDM4E (0.59) | SRCKDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL20589615 | 0.72 | KDM4E (0.59) | SRCKDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL2390290 | 0.72 | ALOX15 (0.43) | SRCARKDM4EUSP2ALDH1A1 | |
| SCHEMBL12299457 | 0.71 | NPC1 (0.48) | ARKDM4EUSP2ALDH1A1IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | SRC 1873/4885AR 2395/4885KDM4E 1199/4885 |
| US-20130079323-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | SRC 1873/4885AR 2395/4885KDM4E 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.